Company intelligence / Profile preview
ONESTX
Seville, Andalusia, Spainonestx.bio ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
ONESTX has demonstrated in animal models (C. elegans and mice) that increasing levels of certain neurosteroids via steroid sulfatase inhibition can improve memory and lifespan. In models of Alzheimer’s disease, this approach led to improvements in cognitive symptoms. The company’s programs are currently at the pre-clinical stage with promising results in both nematode and mammalian systems
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (specifically steroid sulfatase inhibitors)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on ONESTX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONESTX.